Sore throat. Crossing problems and finding solutions
DOI: 10.32364/2618-8430-2022-5-3-228-236
E.Yu. Radtsig1, A.V. Gurov1,2
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2L.I. Sverzhevskiy Research Clinical Institute of Otorhinolaryngology, Moscow, Russian Federation
The article presents a brief review of the current issues relating to the treatment of acute infectious inflammatory diseases associated with sore throat. Painful throat is one of the most common reasons for the administration of systemic antibacterial drugs as a baseline therapy which, in turn, may facilitate a rise in antibiotic resistance. Recently the focus has shifted to the antibacterial therapy impact on the qualitative and quantitative composition of the microbiota. The review elucidates the opportunities of successful etiotropic therapy amid a low risk of the antibiotic resistance development and a lack of the adverse effects on the oropharyngeal microbiota. Updated information is provided characterizing the pharmacological activity of a bacterium-produced non-ribosomal antimicrobial peptide Gramicidin S and Cetylpyridinium chloride, an antiseptic agent. The highest potency of topical medications can be achieved due to the combined action of multiple synergis tic components. A potential combined use of Gramicidin S and Cetylpyridinium chloride is discussed in the review from the standpoint of the risk of antibiotic resistance and the impact on microbiota. The authors conclude that for the treatment of infectious inflammatory diseases of the upper respiratory tract associated with sore throat it is advisable to select biocenosis-saving topical etiotropic therapy.
Keywords: Gramicidin S, non-ribosomal antimicrobial peptides, Cetylpyridinium chloride, topical etiotropic therapy, bactericidal activity, antibiotic resistance, microbiocenosis-saving therapy, pharyngitis, tonsillopharyngitis.
For citation: Radtsig E.Yu., Gurov A.V. Sore throat. Crossing problems and finding solutions. Russian Journal of Woman and Child Health. 2022;5(3):228–236 (in Russ.). DOI: 10.32364/2618-8430-2022-5-3-228-236.
About the authors:
Elena Yu. Radtsig — Dr. Sc. (Med.), Professor, Professor of the Department of Otorhinolaryngology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0003-4613-922X.
Aleksandr V. Gurov — Dr. Sc. (Med.), Professor of the Department of Otorhinolaryngology, Professor of the Department of Microbiology and Virology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; senior researcher of the Division of Epidemiology, Clinical Trials and Prognostic Research, L.I. Sverzhevskiy Research Clinical Institute of Otorhinolaryngology; 18A Build. 2, Zagorodnoe road, Moscow, 117152, Russian Federation; ORCID iD 0000-0001-9811-8397.
Contact information: Elena Yu. Radtsig, e-mail: radtsig_e@rsmu.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
Conflict of interests: A.V. Gurov informed that he has received a grant for performing an independent panel review of the results of the pre-clinical study of Gramycidin S antimicrobial activity against the most prevalent pathogens causing respiratory infections. The study was conducted upon request of AO Valenta Pharm within the implementation of the current plan of company’s research activities by an independent research organization AO NPO "Home of Pharmacy".
Received 09.07.2022.
Revised 02.08.2022.
Accepted 25.08.2022.
2. Krüger K., Töpfner N., Berner R. et al. Clinical Practice Guideline: Sore Throat. Dtsch Arztebl Int. 2021;118(11):188–194. DOI: 10.3238/arztebl.m2021.0121.
3. Wi D., Choi S.H. Positive Rate of Tests for Group a Streptococcus and Viral Features in Children with Acute Pharyngitis. Children (Basel). 2021;8(7):599. DOI: 10.3390/children8070599.
4. Saatchi A., Yoo J.W., Schwartz K.L. et al. Quantifying the Gap between Expected and Actual Rates of Antibiotic Prescribing in British Columbia, Canada. Antibiotics (Basel). 2021;10(11):1428. DOI: 10.3390/antibiotics10111428.
5. Spinks A., Glasziou P.P., Del Mar C.B. Antibiotics for sore throat. Cochrane Database Syst Rev. 2013;2013(11):CD000023. DOI: 10.1002/14651858.CD000023.pub4.
6. Wilcox C.R., Moore M., Little P. Use of antibiotics for acute sore throat and tonsillitis in primary care. Br J Gen Pract. 2022;72(716):136–137. DOI: 10.3399/bjgp22X718793.
7. Cots J.M., Alós J.I., Bárcena M. et al. Recomendaciones para el manejo de la faringoamigdalitis aguda del. Aten Primaria. 2015;47(8):532–543 (in Spanish). DOI: 10.1016/j.aprim.2015.02.002.
8. Alm R.A., Lahiri S.D. Narrow-Spectrum Antibacterial Agents-Benefits and Challenges. Antibiotics (Basel). 2020;9(7):418. DOI: 10.3390/antibiotics9070418.
9. Clinical guidelines. Acute tonsillitis and pharyngitis. 2021. (Electronic resource.) URL: https://cr.minzdrav.gov.ru/recomend/306_2 (access date: 03.08.2022) (in Russ.).
10. Radtsig E.Yu., Evsikova M.M., Lugovaya Yu.V. Clinical and etiological features of the pharynx acute inflammation course in children of different age groups. Pediatriya. Zhurnal im. G.N. Speranskogo. 2021;100(1):130–135 (in Russ.). DOI: 10.24110/0031-403X-2021-100-1-130-135.
11. Menni C., Valdes A.M., Polidori L. et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618–1624. DOI: 10.1016/S0140-6736(22)00327-0.
12. Evsikova M.M., Radtsig E.Yu, Varavina M.A. The role of group A β-hemolytic streptococcus in the etiology of acute inflammatory pathology of the pharynx in children and adolescents. Vestnik otorinolaringologii. 2020;85(1):22–24 (in Russ.). DOI: 10.17116/otorino20208501122.
13. Pallon J., Sundqvist M., Hedin K. A 2-year follow-up study of patients with pharyngotonsillitis. BMC Infect Dis. 2018;18(1):3. DOI: 10.1186/s12879-017-2917-4.
14. Frost H.M., Fritsche T.R., Hall M.C. Beta-Hemolytic Nongroup A Streptococcal Pharyngitis in Children. J Pediatr. 2019;206:268–273.e1. DOI: 10.1016/j.jpeds.2018.10.048.
15. Robinson J.L. Paediatrics: how to manage pharyngitis in an era of increasing antimicrobial resistance. Drugs Context. 2021;10:2020–11–6. DOI: 10.7573/dic.2020-11-6.
16. Schachtel B., Shephard A., Schachtel E. et al. Evidence of the Efficacy of Flurbiprofen 8.75 mg Lozenges for Patients Receiving Antibiotics for Laboratory-Confirmed Streptococcal Pharyngitis. Ear Nose Throat J. 2021:1455613211025754. DOI: 10.1177/01455613211025754.
17. Dao V.A., Overhagen S., Bilstein A. et al. Ectoine lozenges in the treatment of acute viral pharyngitis: a prospective, active-controlled clinical study. Eur Arch Otorhinolaryngol. 2019;276(3):775–783. DOI: 10.1007/s00405-019-05324-9.
18. Havers F.P., Hicks L.A., Chung J.R. et al. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Netw Open. 2018;1(2):e180243. DOI: 10.1001/jamanetworkopen.2018.0243.
19. Catic T., Kapo B., Pintol Z. et al. An Instrument for Rating Quality of Life Related to Sore Throat in Patients Suffering from Acute Pharyngitis or Tonsillitis. Mater Sociomed. 2018;30(1):43–48. DOI: 10.5455/msm.2018.30.43-48.
20. Mistik S., Gokahmetoglu S., Balci E., Onuk F.A. Sore throat in primary care project: a clinical score to diagnose viral sore throat. Fam Pract. 2015;32(3):263–268. DOI: 10.1093/fampra/cmv015.
21. Ovchinnikov A.Yu., Miroshnichenko N.A., Nikolaeva Yu.O. Sore throat. Recent trends in treatment. Bulletin of Otorhinolaryngology=Vestnik otorinolaringologii. 2020;85(4):35–39 (in Russ.). DOI: 10.17116/otorino20208504135.
22. WHO. Resistance to antibiotics. 2018. (Electronic resource.) URL: https://www.who.int/en/news-room/fact-sheets/detail/antibiotic-resistance (access date: 13.08.2022) (in Russ.).
23. Sidorenko S.V. Antimicrobial resistance: mechanisms and ways to overcome. In: Kudryavtsev K.V., Panina Ye.M. eds. Molecular and Biological Aspects of Chemistry, Pharmaceutics and Pharmacology. M.: Izdatel’stvo "Pero"; 2020: 95 (in Russ.).
24. Bin Hafeez A., Jiang X., Bergen P.J., Zhu Y. Antimicrobial Peptides: An Update on Classifications and Databases. Int J Mol Sci. 2021;22(21):11691. DOI: 10.3390/ijms222111691.
25. Essack S., Bell J., Burgoyne D.S. et al. Topical (local) antibiotics for respiratory infections with sore throat: An antibiotic stewardship perspective. J Clin Pharm Ther. 2019;44(6):829–837. DOI: 10.1111/jcpt.13012.
26. Dubos R.J. Studies on a bactericidal agent extracted from a soil bacillus: i. Preparation of the agent. Its activity in vitro. J Exp Med. 1939;70(1):1–10. DOI: 10.1084/jem.70.1.1.
27. Gause G.F., Brazhnikova M.G. Gramicidin S and its use in the treatment of infected wounds. Nature. 1944;154:703. DOI: 10.1038/154703a0.
28. Berditsch M., Afonin S., Reuster J. et al. Supreme activity of gramicidin S against resistant, persistent and biofilm cells of staphylococci and enterococci. Sci Rep. 2019;9(1):17938. DOI: 10.1038/s41598-019-54212-z6-11.
29. Yamamura H., Isshiki K., Fujita Y. et al. Gramicidin S-inspired antimicrobial cyclodextrin to disrupt gram-negative and gram-positive bacterial membranes. Medchemcomm. 2019;10(8):1432–1437. DOI: 10.1039/c9md00229d.
30. Pavithrra G., Rajasekaran R. Gramicidin Peptide to Combat Antibiotic Resistance: A Review. Int J Pept Res Ther. 2020;26:191–199. DOI: 10.1007/s10989-019-09828-0.
31. Enayathullah M.G., Parekh Y., Banu S. et al. Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection. Sci Rep. 2022;12(1):3446. DOI: 10.1038/s41598-022-07341-x.
32. Wenzel M., Rautenbach M., Vosloo J.A. et al. The Multifaceted Antibacterial Mechanisms of the Pioneering Peptide Antibiotics Tyrocidine and Gramicidin S. mBio. 2018;9(5):e00802–e00818. DOI: 10.1128/mBio.00802-18.
33. Hartmann M., Berditsch M., Hawecker J. et al. Damage of the bacterial cell envelope by antimicrobial peptides gramicidin S and PGLa as revealed by transmission and scanning electron microscopy. Antimicrob Agents Chemother. 2010;54(8):3132–3142. DOI: 10.1128/AAC.00124-10.
34. Wenzel M., Kohl B., Münch D. et al. Proteomic response of Bacillus subtilis to lantibiotics reflects differences in interaction with the cytoplasmic membrane. Antimicrob Agents Chemother. 2012;56(11):5749–5757. DOI: 10.1128/AAC.01380-12.
35. Zakharova I.N., Geppe N.A., Sugyan N.G. et al. Topical etiotropic drugs in therapy of infectious inflammatory diseases of pharynx in preschool children. Results of multicenter randomized comparative clinical trial. Rossiiskaya otorinolaringologiya. 2021;20(1):99–113 (in Russ.). DOI: 10.18692/1810-4800-2021-1-99-113.
36. Hancock R.E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis. 2001;1(3):156–164. DOI: 10.1016/s14733099(01)00092-5.27.
37. Pavithrra G., Rajasekaran R. Gramicidin Peptide to Combat Antibiotic Resistance: A Review. Int J Pept Res Ther. 2020;26:191–199. DOI: 10.1007/s10989-019-09828-0.
38. Bulgakova V.G., Grushina V.A., Polin A.N. Isolation and investigation of Staphylococcus aureus strains resistant to the membrane active antibiotic, gramicidin S. Antibiot Khimioter. 1993;38(8–9):22–25. PMID: 7518668.
39. Wesgate R., Evangelista C., Atkinson R. et al. Understanding the risk of emerging bacterial resistance to over the counter antibiotics in topical sore throat medicines. J Appl Microbiol. 2020;129(4):916–925. DOI: 10.1111/jam.14682.
40. Guan Q., Huang S., Jin Y. et al. Recent Advances in the Exploration of Therapeutic Analogues of Gramicidin S, an Old but Still Potent Antimicrobial Peptide. J Med Chem. 2019;62(17):7603–7617. DOI: 10.1021/acs.jmedchem.9b00156.
41. Kondejewski L.H., Farmer S.W., Wishart D.S. et al. Modulation of structure and antibacterial and hemolytic activity by ring size in cyclic gramicidin S analogs. J Biol Chem. 1996;271(41):25261–25268. DOI: 10.1074/jbc.271.41.25261.
42. Yonezawa H., Kaneda M., Tominaga N. et al. Adsorption of 14C-labeled gramicidin S on cell of bacteria. J Biochem. 1981;90(4):1087–1091. DOI: 10.1093/oxfordjournals.jbchem.a133560.
43. Derbal S., Hensler M., Fang W., Nizet V. et al. On resin amino acid side chain attachment strategy for the head to tail synthesis of new glutamine containing gramicidin-S analogs and their antimicrobial activity. Bioorg Med Chem Lett. 2010;20(19):5701–5704. DOI: 10.1016/j.bmcl.2010.08.015.
44. Gurov A.V., Borovkova K.E., Kryshen K.L. et al. Evaluation of the bactericidal activity of gramicidin C against clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus in single and repeated exposure. Antibiotics and Chemotherapy. 2022;67(7–8):8–18 (in Russ.). DOI: 10.37489/0235-2990-2022-67-7-8-8-18.
45. Gurov A.V., Muzhichkova A.V., Yushkina M.A. An Integrated Approach to Treatment of Inflammatory Diseases of the Upper Respiratory Tract. Lechebnoe delo. 2021;3:23–29 (in Russ.). DOI: 10.24412/2071-5315-2021-12356.
46. Hagan H.H. Cetylpyridinium chloride as a cutaneous germicide in major surgery. Arch Sur. 1946;52(2):149. DOI: 10.1001/archsurg.1946.01230050153003.
47. Mukherjee P.K., Esper F., Buchheit K. et al. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis. 2017;17(1):74. DOI: 10.1186/s12879-016-2177-8.
48. Mao X., Auer D.L., Buchalla W. et al. Cetylpyridinium Chloride: Mechanism of Action, Antimicrobial Efficacy in Biofilms, and Potential Risks of Resistance. Antimicrob Agents Chemother. 2020;64(8):e00576–e00620. DOI: 10.1128/AAC.00576-20.
49. Mao X., Hiergeist A., Auer D.L. et al. Ecological Effects of Daily Antiseptic Treatment on Microbial Composition of Saliva-Grown Microcosm Biofilms and Selection of Resistant Phenotypes. Front Microbiol. 2022;13:934525. DOI: 10.3389/fmicb.2022.934525.
50. Radford J.R., Beighton D., Nugent Z., Jackson R.J. Effect of use of 0.05% cetylpyridinium chloride mouthwash on normal oral flora. J Dent. 1997;25(1):35–40. DOI: 10.1016/s0300-5712(95)00116-6.
51. Esper F.P., Dimaano M.L., Popkin D. et al. Novel Antiviral prevents Viral Upper Respiratory Infections in vitro and in vivo. In: ID Week 2015. San Diego: Infectious Diseases Society of America (IDSA); 2015.
52. Melekhina E.V., Muzyka A.D., Ponezheva Zh.B., Gorelov A.V. Cetylpyridinium chloride as a part of a combined medication for adults and children during the COVID-19 pandemic: established and perspective use. Russian Medical Inquiry. 2021;5(11):728–736 (in Russ.). DOI: 10.32364/2587-6821-2021-5-11-728-736.
53. Geppe N.A., Karpova E.P., Dronov I.A. et al. Topical drugs for the treatment of non-streptococcal acute tonsillopharyngitis in children: results of a multicenter study. Bulletin of Otorhinolaryngology=Vestnik otorinolaringologii. 2020;85(6):89–94 (in Russ.). DOI: 10.17116/otorino20208506184.
54. Radtsig E.Yu., Kotova E.N., Zlobina N.V. et al. Acute pharyngitis and tonsillopharyngitis in children: the problem of choosing a medication for local application. Clinical Practice in Pediatrics. 2016;11(4):18–23 (in Russ.). DOI: 10.20953/1817-7646-2016-4-18-23.
55. Radtsig E.Yu., Pivneva N.D., Kotova E.N. Treatment of inflammatory diseases of the throat in children: a systemic antibiotic or a symptomatic therapy? Pediatriya. Zhurnal im. G.N. Speranskogo. 2015;94(3):135–141. (in Russ.). Available at: https://pediatriajournal.ru/files/upload/mags/346/2015_3_4314.pdf (аccessed: 14.09.2022).
56. Dubourg G., Edouard S., Raoult D. Relationship between nasopharyngeal microbiota and patient’s susceptibility to viral infection. Expert Rev Anti Infect Ther. 2019;17(6):437–447. DOI: 10.1080/14787210.2019.1621168.
57. Nesbitt H., Burke C., Haghi M. Manipulation of the Upper Respiratory Microbiota to Reduce Incidence and Severity of Upper Respiratory Viral Infections: A Literature Review. Front Microbiol. 2021;12:713703. DOI: 10.3389/fmicb.2021.713703.
57. Gurov A.V., Yushkina M.A., Muzhichkova A.V. Microbiocenosis-regulating therapy of inflammatory pathology of the oropharynx. Bulletin of Otorhinolaryngology=Vestnik otorinolaringologii. 2021;86(6):51–56 (in Russ.). DOI: 10.17116/otorino20218606151.
58. Radtsig E.Yu., Sel’kova E.P., Zlobina N.V. The role of respiratory viruses in nasopharynx mikrobiome in children. Rossijskaya otorinolaringologiya. 2017;3(88):72–77 (in Russ.). DOI: 10.18692/1810-4800-2017-3-72-77.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
